Experimental cocktail aims to shrink untreatable esophageal tumors
NCT ID NCT07086469
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding the drug surufatinib to standard chemo-immunotherapy and radiation can help people with advanced esophageal cancer that cannot be removed by surgery. The study will enroll 69 participants in China and track how long they live without the cancer getting worse. The goal is to see if this combination is safe and effective enough to improve outcomes for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
surufatinib (an anti-cancer drug) combined with chemotherapy (albumin-bound paclitaxel, cisplatin), immunotherapy (toripalimab), and radiation
What this could lead to
If successful, this combination could shrink or control advanced esophageal tumors that cannot be surgically removed, potentially improving survival without the need for surgery.
What could go wrong
This is an early phase II trial with only 69 participants, so results may not apply to all patients. The drug combination may cause significant side effects, and it is not yet known if it works better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••